Refers to an inhalable dry powder Pharmaceutical composition comprising: a) an inhibitor of phosphodiesterase 4 (PDE4) in the form of enantiomer (-) of formula (i) wherein R1 and R2 are each OR3, hnso2r4 or alkyl (C1 - C6) optionally substituted by HalogenWhere R3 is (C1 - C6 alkyl or cycloalkyl, optionally substituted by Halogen) (C3 - C7) R is alkyl (c1-c4) optionally substituted by Halogen n is 0 OR 1 being Preferred compounds: 1 - (Cyclopropylmethoxy Difluoromethoxy - 3 - 4 - phenyl) - 2 - (3,5 - Dichloro pyridin-4-yl) - acid ethyl ester (-) - 3 - CLC Lopropilmetoxi - 4 - metansulfonilamino benzoic acid, 2 - (Cyclopropylmethoxy Difluoromethoxy - 3 - 4 - phenyl) - 2 - (3,5 - Dichloro - 1 - Oxy pyridin-4-yl) - acid ethyl ester (-) - 3 - (Cyclopropylmethoxy - 4 - metansulfonilamino benzoic acid, among others (b) a pharmacologically Inert Vehicle such as lactose and (c) Magnesium Stearate as a LUBRICANT in an amount of 0.01% 2% by weight of the composition. The pharmaceutical composition is useful in the treatment of chronic obstructive pulmonary disease, asthmaSE REFIERE A UNA COMPOSICION FARMACEUTICA DE POLVO SECO INHALABLE QUE COMPRENDE: A) UN INHIBIDOR DE FOSFODIESTERASA 4 (PDE4) EN LA FORMA DE ENANTIOMERO (-) DE FORMULA (I) DONDE R1 Y R2 SON CADA UNO OR3, HNSO2R4 O ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON HALOGENO, EN DONDE R3 ES ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON HALOGENO O CICLOALQUILO(C3-C7) R4 ES ALQUILO(C1-C4) OPCIONALMENTE SUSTITUIDO CON HALOGENO n ES 0 O 1 SIENDO COMPUESTOS PREFERIDOS: 1-(3-CICLOPROPILMETOXI-4-DIFLUOROMETOXI-FENIL)-2-(3,5-DICLORO-PIRIDIN-4-IL)-ETIL ESTER DEL ACIDO (-)-3-CICLOPROPILMETOXI-4-METANSULFONILAMINO-BENZOICO, 1-(3-CICLOPROPILMETOXI-4-DIFLUOROMETOXI-FENIL)-2-(3,5-DICLORO-1-OXI-PIRIDIN-4-IL)-ETIL ESTER DEL ACIDO (-)-3-CICLOPROPILMETOXI-4-METANSULFONILAMINO-BENZOICO, ENTRE OTROS B) UN VEHICULO FARMACOLOGICAMENTE INERTE TAL COMO LACTOSA Y C) UN LUBRICANTE TAL COMO ESTEARATO DE MAGNESIO EN UNA CANTIDAD DE 0,01% A 2% EN PE
